Insulin detemir in the management of type 2 diabetes in non-Western countries: Safety and effectiveness data from the A1chieve observational study

Abstract: Aims: This subgroup analysis of the A1chieve study examined data from 15,545 people who started treatment with insulin detemir±oral glucose-lowering drugs in routine clinical care.Methods: A1chieve was a 24-week, international, prospective, non-interventional study of people with type 2 diabetes from non-Western nations starting treatment with basal insulin detemir, bolus insulin aspart or biphasic insulin aspart 30, alone or in combination, to evaluate their safety and effectiveness in routine clinical practice.Results: HbA1c for the global cohort improved after 24 weeks from 9.5±1.6% by −2.0±1.6% [80±17 by −22±17 mmol/mol] (−2.1±1.6% [−23±17 mmol/mol] for insulin-naïve participants; −1.6±1.7% [−17±19 mmol/mol] for prior insulin users). Fasting plasma glucose and postprandial plasma glucose were also significantly reduced (p
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Tags: Clinical Care and Education Source Type: research